Biocartis' rapid Ebola Triage Test enters field-trial phase

Biocartis said on Tuesday that its Rapid Ebola Virus Triage Test has entered the field-trial phase, in partnership with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp, Belgium.

The purpose of the Idylla system is to provide accurate results in a timely manner and to be able to perform in the field and in remote areas. Biocartis said only 0.2 ml of blood is needed to determine in approximately 90 minutes whether a subject is infected with the Ebola virus.

“This test aims not only to improve the diagnosis of the Ebola virus for hard-pressed health care professionals in the field, but to lay the foundations for a better and faster diagnostic infrastructure after the current outbreak has receded, both in this region and around the world," Biocartis CEO Rudi Pauwels said. "One of the lessons of the Ebola outbreak has been the urgent need for faster and more accurate diagnostics. Biocartis is pleased to be working, alongside prestigious partners, on what it believes could offer a viable solution for health care workers around the world to enable faster testing of infectious diseases in virtually any setting.”

Biocartis will conduct field tests of the cartridges in West Africa after successful tests using synthetic virus samples in Belgium and the U.S.